June Off to a Poor ...
Health Care: Drugs
AVEO Pharmaceuticals Inc. (AVEO: NASDAQ)
$12.46 -0.27 | -2.12%
06/01/12 - 04:00 PM ET
297.54K / 403.40K
Vol / Avg. Vol:12.48 / 12.73
Open / Prev. Close:12.33 - 12.62
Today's Range:10.40 - 21.55
52 Wk Range:-27.56%
Performance YTD:TheStreet Rating:
Portfolios with AVEO
- Portfolio NameUser Type
- ProSeth Klarman - Baupost Group
- Contributor7 Cancer Drug Stocks to Kno...
- ContributorBreakout Stocks Of The Week...
- ContributorHot Biotech Trades for Seco...
- Contributor10 Health-Care Stocks Outpe...
- ContributorCancer Drug Stocks to Trade...
Latest AVEO Headlines from TheStreet
- ASCO '12 Stocks: Winners and Losers 06.04.12 | 06:06 am
- ASCO 2012 Live Blog -- Saturday 06.02.12 | 07:06 am
- AVEO Stock Falls On Unusually High Volume (AVEO) 05.17.12 | 11:05 am
- ASCO '12 Abstract Dump: Cancer Stocks in Focus (Update) 05.17.12 | 06:05 am
- ASCO '12 Abstract Dump: Cancer Stocks in Focus 05.16.12 | 06:05 pm
- Biotech Stock Mailbag: AVI, Aveo, Spectrum 04.27.12 | 06:04 am
- AVEO Stock Hits New 52-Week Low (AVEO) 04.11.12 | 11:04 am
- AVEO Pharmaceuticals Inc. Stock Downgraded (AVEO) 04.10.12 | 05:04 am
- 7 Cancer Drug Stocks to Know Right Now 03.14.12 | 09:03 am
- AVEO Stock Hits New 52-Week Low (AVEO) 03.12.12 | 01:03 pm
Press Releases for AVEO
- AVEO And Astellas Announce TAURUS Patient Preference Clinical Study Comparing Tivozanib With Sunitinib In First-Line Kidney Cancer - Business Wire 06.04.12 | 07:06 am
- AVEO Oncology To Host Conference Call And Webcast To Review Phase 3 TIVO-1 Data Presented At ASCO - Business Wire 05.30.12 | 06:05 am
- AVEO Oncology To Present At The Jefferies 2012 Global Healthcare Conference - Business Wire 05.29.12 | 06:05 am
- AVEO Initiates Phase 1 Study Of AV-203, An ERBB3 Inhibitory Antibody, In Advanced Solid Tumors - Business Wire 05.23.12 | 06:05 am
- AVEO And Astellas Announce Positive Findings From TIVO-1 Superiority Study Of Tivozanib In First-Line Advanced RCC - Business Wire 05.16.12 | 06:05 pm
- AVEO Reports First Quarter 2012 Financial Results And Recent Developments - Business Wire 05.03.12 | 06:05 am
- AVEO Announces Preliminary Results Of Exploratory Phase 2 Study Evaluating HGF Inhibitor In First-Line Patients With Advanced Lung Cancer - Business Wire 05.02.12 | 06:05 am
- AVEO Pharmaceuticals, Inc. To Present At Upcoming Investment Conferences - Business Wire 04.30.12 | 06:04 am
- AVEO Pharmaceuticals, Inc. Announces Timing For First Quarter Financial Results, Webcast And Conference Call - Business Wire 04.26.12 | 06:04 am
- AVEO Announces Publication Of Positive Tivozanib Phase 2 Clinical Trial Results In Journal Of Clinical Oncology - Business Wire 04.12.12 | 06:04 am
Partner Headlines for AVEO
- Biotechnology Stocks To Watch Ahead Of ASCO 2012: Part 3 - Seeking Alpha 05.25.12 | 08:05 pm
- 4 Compelling Alternatives To Vertex Pharma - Seeking Alpha 02.23.12 | 08:02 am
- 5 Stocks That Could Be Takeover Targets - Seeking Alpha 02.01.12 | 08:02 am
- Tracking Seth Klarman's Baupost Group Holdings - Seeking Alpha 10.18.11 | 09:10 am
- Zacks #1 Rank Additions for Tuesday - Tale of the Tape - Zacks 09.27.11 | 09:09 am
- Seth Klarman's Big Q2 Bets - Seeking Alpha 09.19.11 | 09:09 am
- Seth Klarman's Favorite Stock Picks - Seeking Alpha 07.26.11 | 09:07 am
- Seth Klarman's Top 10 Long Ideas - Seeking Alpha 07.08.11 | 08:07 am
- Zacks #1 Rank Additions for Thursday - Tale of the Tape - Zacks 06.23.11 | 09:06 am
- Zacks #1 Rank Additions for Tuesday - Tale of the Tape - Zacks 06.21.11 | 09:06 am
